Applied Therapeutics Inc. (APLT) shares plummeted by 5.42% in the pre-market session on Monday, December 2, 2024, following a significant downgrade and price target cut by UBS analysts.
According to UBS, they have downgraded their rating on Applied Therapeutics from Buy to Neutral, citing concerns about the company's prospects. Along with the downgrade, UBS has also slashed their price target for the stock from $13 to just $2.
The steep downgrade and price target reduction by a prominent Wall Street firm like UBS appears to be the primary driver behind the sharp sell-off in Applied Therapeutics' shares on Monday morning.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。